{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:28:02Z","timestamp":1794108482913,"version":"4.8.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3,1]]},"DOI":"10.1097\/qai.0b013e31823ff052","type":"journal-article","created":{"date-parts":[[2011,11,12]],"date-time":"2011-11-12T11:12:05Z","timestamp":1321096325000},"page":"245-252","source":"Crossref","is-referenced-by-count":76,"title":["Efavirenz Pharmacokinetics During the Third Trimester of Pregnancy and Postpartum"],"prefix":"10.1097","volume":"59","author":[{"given":"Tim R.","family":"Cressey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Stek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Capparelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chureeratana","family":"Bowonwatanuwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinart","family":"Prommas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pannee","family":"Sirivatanapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prapap","family":"Yuthavisuthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanon","family":"Neungton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brookie M.","family":"Best","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Mirochnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210131","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/archinte.162.3.355","article-title":". Periconceptional exposure to efavirenz and neural tube defects.","volume":"162","author":"De Santis","year":"2002","journal-title":"Arch Intern Med"},{"key":"R2-4-20210131","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00002030-200201250-00025","article-title":". Myelomeningocele in a child with intrauterine exposure to efavirenz.","volume":"16","author":"Fundaro","year":"2002","journal-title":"AIDS"},{"key":"R4-4-20210131","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":". The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIVAIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.","volume":"306","author":"Ward","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R5-4-20210131","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ajog.2004.08.030","article-title":". Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.","volume":"192","author":"Tracy","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"R6-4-20210131","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/QAI.0b013e31820fd093","article-title":". Atazanavir Pharmacokinetics With and Without Tenofovir during Pregnancy.","volume":"56","author":"Mirochnick","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R7-4-20210131","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1097\/01.aids.0000247114.43714.90","article-title":". Reduced lopinavir exposure during pregnancy.","volume":"20","author":"Stek","year":"2006","journal-title":"AIDS"},{"key":"R10-4-20210131","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1128\/AAC.48.3.824-831.2004","article-title":". Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories.","volume":"48","author":"Holland","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-4-20210131","first-page":"4","article-title":"C, Back D, Blaschke T, et al.. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents.","volume":"3","year":"2006","journal-title":"Rev Antivir Ther"},{"key":"R12-4-20210131","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.2165\/00003088-200443150-00002","article-title":"Pharmacokinetics of antiretrovirals in pregnant women.","volume":"43","author":"Mirochnick","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R13-4-20210131","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1468-1293.2008.00553.x","article-title":". Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.","volume":"9","author":"Capparelli","year":"2008","journal-title":"HIV Med"},{"key":"R14-4-20210131","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/QAI.0b013e3181e9871b","article-title":". Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.","volume":"55","author":"Lamorde","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R15-4-20210131","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1468-1293.2010.00874.x","article-title":". Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women.","volume":"12","author":"Izurieta","year":"2011","journal-title":"HIV Med"},{"key":"R16-4-20210131","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.meegid.2006.08.004","article-title":"Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update.","volume":"7","author":"Cressey","year":"2007","journal-title":"Infect Genet Evol"},{"key":"R17-4-20210131","first-page":"2391","article-title":". Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.","volume":"18","author":"Haas","year":"2004","journal-title":"Aids"},{"key":"R18-4-20210131","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/jac\/dkp351","article-title":". Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.","volume":"64","author":"Chantarangsu","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R20-4-20210131","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1097\/QAD.0b013e32833a2a14","article-title":". Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts.","volume":"24","author":"Ford","year":"2010","journal-title":"AIDS"},{"key":"R23-4-20210131","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1097\/QAD.0b013e32833ce57d","article-title":". Pharmacokinetics and virologic response of zidovudinelopinavirritonavir initiated during the third trimester of pregnancy.","volume":"24","author":"Cressey","year":"2010","journal-title":"AIDS"},{"key":"R24-4-20210131","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1097\/QAD.0b013e328347f7e9","article-title":". Thai HIV-1-infected women do not require a dose increase of lopinavirritonavir during the third trimester of pregnancy.","volume":"25","author":"Ramautarsing","year":"2011","journal-title":"AIDS"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAI.0b013e31823ff052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:54:31Z","timestamp":1620971671000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201203010-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,1]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31823ff052","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3,1]]}}}